Routine board refresh and CEO contract renewal — no immediate catalyst. Monitor upcoming pipeline catalysts (roxadustat Phase 3 LR-MDS trial update, FG-3246 Phase 2 data) for fundamental value drivers.
Price Chart
Executive Summary
Kyntra Bio appointed Andrew E. Singer as a Class III director and Audit Committee member effective October 1, 2026, replacing Maykin Ho who resigned effective September 30, 2026. The company also entered into a new Change-in-Control and Severance Agreement with CEO Thane Wettig on substantially the same terms as the prior agreement, with a three-year term ending October 2, 2029. These are routine board and executive compensation changes with no material financial impact.
Key Facts
- Andrew E. Singer appointed as Class III director and Audit Committee member effective October 1, 2026
- Maykin Ho resigned from the Board effective September 30, 2026 — not due to any disagreement with the company
- New Change-in-Control and Severance Agreement with CEO Thane Wettig executed September 30, 2026, with substantially same terms as prior agreement
- New CEO severance agreement has a three-year term ending October 2, 2029
- No material changes to compensation or benefits payable under the CEO severance agreement
Financial Impact
No financial figures disclosed in the filing — routine director appointment and CEO severance renewal with no material changes
Risk Factors
- No material risks identified from this filing — standard director transition and executive compensation renewal
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409819 |
| Document: kynb-ex99_1.htm | 0001193125-26-409819 |
| Document: 0001193125-26-409819-index-headers.html | 0001193125-26-409819 |
| Document: 0001193125-26-409819-index.html | 0001193125-26-409819 |
| Document: 0001193125-26-409819.txt | 0001193125-26-409819 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | 3 | $6.13 $5.57 | ▼ −9.22% | ▼ −8.24% | $4.50 (−26.59%) |
Oct 6, 2026 20d ago | 8-K | $6.13 $5.57 | ▲ +9.22% | ▲ +8.24% | $4.50 (+26.59%) |
Oct 1, 2026 25d ago | 8-K | $6.50 $5.96 | ▼ −8.31% | ▼ −9.61% | $4.50 (−30.77%) |
Jun 9, 2026 19w ago | 8-K | $6.69 $6.91 | ▲ +3.29% | ▼ −0.14% | $4.50 (−32.74%) |
May 11, 2026 24w ago | Press Release | $7.23 $6.83 | ▼ −5.47% | ▼ −5.54% | $4.50 (−37.72%) |
Mar 16, 2026 32w ago | Press Release | $7.37 $6.75 | ▲ +8.41% | ▲ +5.76% | $4.50 (+38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers